Charles River Labs Appoints New Director

Details

announced on January 22, 2024, the appointment of Ms. Reshema Kemps-Polanco to its Board of Directors, increasing the Board size from eleven to twelve members. Ms. Kemps-Polanco, with 25 years of pharmaceutical industry experience, will also join the Compensation Committee and Strategic Planning and Capital Allocation Committee. She is currently the Executive Vice President and Chief Commercial Officer of Novartis US. As part of her compensation, Ms. Kemps-Polanco will receive an initial equity award and cash retainer.

Items reported

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides essential services to the pharmaceutical, biotechnology, and life sciences industries. The company specializes in preclinical and clinical lab services, offering clients a comprehensive suite of drug discovery and development services that expedite the process of getting new drugs and therapies to the market. Notably, Charles River's facilities offer expertise in the fields of oncology, immunology, and neuroscience, making it a critical partner for companies working in these therapeutic areas. The firm operates globally, enhancing its customers' ability to operate internationally through its wide network of laboratories and testing facilities. By enabling more efficient drug development cycles and reducing the time to market for new therapies, Charles River Laboratories plays a crucial role in the advancement of medical science and patient care worldwide. The company's commitment to high standards of animal welfare and ethical practices further underscores its reputation as a leader in quality and reliability within the research community.